Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 821-830

  Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; Muscle invasive bladder cancer; Neoadjuvant

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; VINBLASTINE; TUMOR MARKER;

ADJUVANT THERAPY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; CANCER INVASION; COMPARATIVE STUDY; DISEASE COURSE; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MUSCLE TUMOR; PATHOLOGY; RISK FACTOR;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 68849112484     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.36     Document Type: Review

References (53)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
3. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J. Urol. 131(6), 1069-1072 (1984).
4. Ghoneim MA, Ashamallah AK, Awaad HK, Whitmore WF Jr. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J. Urol. 134(2), 266-268 (1985).
5. Huncharek M, Muscat J, Geschwind JF. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res. 18(3B), 1931-1934 (1998).
6. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12), 2448-2458 (1989).
7. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8(6), 1050-1055 (1990).
8. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
9. Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argumen in favor. Nat. Clin. Pract. Urol. 5(9), 484-485 (2008).
10. North S. Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder? Can. Urol. Assoc. J. 2(3), 222-224 (2008).
11. So A. Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer. Can. Urol. Assoc. J. 2(3), 225-227 (2008).
12. Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J. Urol. 24(5), 531-542 (2006).
13. Suttmann H, Kamradt J, Lehmann J, Stockle M. Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy. BJU Int. 100(6), 1225-1228 (2007).
14. Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(1 Suppl.), 62-79 (2007).
15. Dotan ZA, Kavanagh K, Yossepowitch O et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J. Urol. 178(6), 2308-2312 (2007).
16. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003).
17. Donat SM, Shabsigh A, Savage C et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol. 55, 177-186 (2008).
18. International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354(9178), 533-540 (1999).
19. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol. 155(6), 1903-1906 (1996).
20. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2. Scand. J. Urol. Nephrol. 36(6), 419-425 (2002).
21. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and mera-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48(2), 202-205 (2005).
22. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171(2 Pt 1), 561-569 (2004).
23. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115(5), 988-996 (2009).
24. Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol. 175(4), 1262-1267 (2006).
25. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur. Urol. 50(6), 1176-1182 (2006).
26. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol. 169(1), 110-115 (2003).
27. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145(3), 459-467 (1991).
28. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153(1), 47-52 (1995).
29. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155(2), 495-499 (1996).
30. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48(2), 189-199 (2005).
31. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 148(2 Pt 1), 302-306 (1992).
32. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153(1), 47-52 (1995).
33. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol. Dial. Transplant. 16(5), 1042-1046 (2001).
34. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133(3), 403-407 (1985).
35. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC Phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42(1), 50-54 (2006).
36. Loehrer PJS, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10(7), 1066-1073 (1992).
37. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J. Clin. Oncol. 24(35), 5545-5551 (2006).
38. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase 2 trial. Eur. Urol. 52(1), 134-141 (2007).
39. Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97(9), 2180-2186 (2003).
40. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100(8), 1639-1645 (2004).
41. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25(6), 563-571 (2007).
42. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol. 2(10), 502-510 (2005).
43. Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014-1024 (2004).
44. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259-1264 (1994).
45. Esrig D, Spruck CH 3rd, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143(5), 1389-1397 (1993).
46. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6(9), 678-686 (2005).
47. Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst. 90(14), 1072-1079 (1998).
48. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7(8), 2440-2447 (2001).
49. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br. J. Cancer 71(4), 831-835 (1995).
50. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84(16), 1251-1256 (1992).
51. Wild PJ, Kunz-Schughart LA, Stoehr R et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int. J. Oncol. 27(2), 385-391 (2005).
52. Inoue K, Slaton JW, Karashima T et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 6(12), 4866-4873 (2000).
53. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7(7), 1957-1962 (2001).